Publication protocol
"Spleens and tumors were excised from the 4T1 tumor-bearing mice. Single cell suspensions were produced by homogenizing the spleen samples, and the tumors were minced and subsequently digested with 500 U/mL collagenase type IV (Sigma) for 1 h at 37 °C with agitation. The resulting single cell suspensions were suspended in RPMI 1640 with 10% fetal calf serum (FCS, Gibco, England).
To stain myeloid-derived suppressor cells (MDSCs), anti-CD11b FITC (clone M1/70, BD Biosciences) and anti-Gr-1 APC (clone RB6-8C5, BD Biosciences) were added to cells suspended in PBS with 3% FCS and incubated for 30 min. Anti-CD4 FITC (clone H129.19, BD Biosciences) and anti-CD25 PE (clone PC61, BD Biosciences) antibodies were used to stain the cell surface of regulatory T cells (Tregs). The cells were then fixed and permeabilized for intracellular staining, and an anti-Foxp3 APC (clone FJK16s, eBioscience) antibody was added. To analyze CD4+ IFN-γ+ T cells and cytotoxic T lymphocytes (CTLs) expressing granzyme B, anti-CD4 FITC (clone H129.19, BD Biosciences), anti-CD8a PerCP (clone 53–6.7, BD Biosciences), and anti-IFN-γ APC (clone XMG1.2, BD Biosciences) were added to the cells and incubated for 30 min. Cells were then fixed and permeabilized, and intracellular staining was performed using an anti-granzyme B PE antibody (clone NGZB, eBioscience). All staining reactions were performed in a final volume of 100 μl at 4 °C. Data were acquired using a FACS Calibur flow cytometer (BD Biosciences, San Diego, CA, USA) and analyzed using FlowJo v7.6.2 software (Tree Star Inc., Ashland, OR, USA)."
Full paper
Login or
join for free to view the full paper.
Videos
Check out videos that might be relevant for performing Flow cytometry Anti-bodies Mouse - FOXP3 using FOXP3 Monoclonal Antibody (FJK-16s), APC, eBioscience™ from eBioscience. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.
We haven't found any additional videos for this experiment / product combination yet.